Ion mobility spectrometry for the detection of volatile organic compounds in exhaled breath of patients with lung cancer: results of a pilot study

Westhoff, M.; Litterst, P; Freitag, Lutz; Urfer, Wolfgang; Bader, Sabine; Baumbach, J. I.

doi:10.1136/thx.2008.099465

Cited by 230 publications

(169 citation statements)

References 18 publications

Supporting

Mentioning

169

Contrasting

Order By: Relevance

“…The use of metabolomics, proteomics and new modes of spectrometry further facilitate exhaled biomarker research [101][102][103][104][105][106][107][108][109][110][111][112][113]. Metabolomic pattern determined by using nuclear magnetic resonance measurements in EBC has been shown to discriminate between healthy and asthmatic children [111].…”

Section: Future Developments In Breath Testingmentioning

confidence: 99%

Exhaled biomarkers in lung cancer

et al. 2009

View full text Add to dashboard Cite

Lung cancer is the leading cause of cancer death. Results of therapeutic interventions are particularly discouraging when the disease is discovered in an advanced stage. Early diagnosis is limited by the fact that the disease usually develops asymptomatically and available screening methods do not fulfil the requirements for reliable discrimination between patients with lung cancer and subjects not suffering from the disease. Breath sampling is completely noninvasive and provides a potentially useful approach to screening lung cancer. Exhaled biomarkers contain both volatile and nonvolatile molecules. The profile of volatile organic compounds is different in patients with lung cancer than in control subjects. In exhaled breath condensate, the proteomic profile of breath from cancer patients differs from that of healthy smokers. We reviewed the scientific evidence demonstrating that a unique chemical signature can be detected in the breath of patients with lung cancer and that the exhaled breath biomarker profile could aid clinical decision making.KEYWORDS: Biomarker, electronic nose, exhaled breath, exhaled breath condensate, lung cancer, smell L ung cancer is the leading cause of global cancer death in both males and females. According to the most recent projection of global mortality, by 2030 it will emerge as the third and the fifth leading cause of death in highand middle-income countries, respectively [1,2]. Figures on disease outcome measures are very discouraging as even with the most advanced treatment strategies ,86% of lung cancer patients die within 5 yrs of diagnosis. With early detection and treatment, however, the 5-yr survival rate improves dramatically from 20% in patients with stage III lung cancer to 70% in patients with stage I disease [3]. Researchers, therefore, have sought out screening tests to detect lung cancer in the earliest stages and several promising new approaches have been proposed for this purpose, such as computer-assisted image analysis of chest radiographs, spiral computed tomography (CT) scanning, PCR-based assays of sputum and fluorescence bronchoscopy [4][5][6][7].Breath chemical tests have a broad spectrum of applications ranging from the US Food and Drug Administration-approved exhaled nitric oxide fraction (FeNO) measurement to monitor the effect of anti-inflammatory treatment in asthma, to volatile organic compound (VOC) determination and nonvolatile biomarker profiling in the cooled breath sample called exhaled breath condensate (EBC) [8][9][10][11]. Being completely noninvasive, sampling of the breath allows clinicians and researchers to assess different body functions in a flexible manner. Breath collection can be performed even in very severe patients and also repeated within short intervals. Therefore, breath testing is considered to be a potentially ideal candidate for screening purposes. Besides widely known constituents such as nitrogen, oxygen, carbon dioxide, inert gases and water vapour, exhaled breath also consists of thousands of volatile and nonv...

show abstract

Section: Future Developments In Breath Testingmentioning

confidence: 99%

Exhaled biomarkers in lung cancer

et al. 2009

View full text Add to dashboard Cite

show abstract

“…IMS is a well-known method to analyze chemical substance using gas-phase mobility in a weak electric field [14][15][16], and is more and more used in the detection of explosives, drugs, chemical warfare agents, biological and medical samples [17][18][19][20][21][22][23][24][25]. Unlike the mass spectrometry [26,27], which operates in vacuum, IMS detects chemical compounds at atmospheric pressure.…”

Section: Introductionmentioning

confidence: 99%

Computational fluid dynamics-Monte Carlo method for calculation of the ion trajectories and applications in ion mobility spectrometry

Han

Cheng

et al. 2012

International Journal of Mass Spectrometry

View full text Add to dashboard Cite

“…The major parameters are summarized elsewhere [8][9][10][11][12][19][20][21][22][23]. In this spectrometer a 550 MBq 63 Ni β-radiation source was applied for the ionization of the carrier gas (air).…”

Section: Methodsmentioning

confidence: 99%

“…Another approach is the ion mobility spectroscopy (IMS), were about 10 ml human breath will be analyzed directly and without any pre-enrichment. Two different types of IMS, such coupled to multi-capillary columns (MCC/IMS) [7][8][9][10][11][12][13][14][15] and differential mobility spectrometers [16,17] were used.…”

Section: Introductionmentioning

confidence: 99%

MCC/IMS as potential noninvasive technique in the diagnosis of patients with COPD with and without alpha 1-antitrypsin deficiency

Koczulla

Hattesohl

Schmid

et al. 2011

Int. J. Ion Mobil. Spec.

View full text Add to dashboard Cite

Ion mobility spectrometry for the detection of volatile organic compounds in exhaled breath of patients with lung cancer: results of a pilot study

Abstract: Background: Analysis of exhaled breath, especially of volatile organic compounds (VOCs

Cited by 230 publications

References 18 publications

Exhaled biomarkers in lung cancer

Exhaled biomarkers in lung cancer

Computational fluid dynamics-Monte Carlo method for calculation of the ion trajectories and applications in ion mobility spectrometry

MCC/IMS as potential noninvasive technique in the diagnosis of patients with COPD with and without alpha 1-antitrypsin deficiency

Contact Info

Product

Resources

About